Seres Therapeutics (MCRB) FCF Margin (2016 - 2026)

Seres Therapeutics has disclosed FCF Margin across 10 years of filings, most recently posting 3042.66% for Q2 2026.

• In Q2 2026, FCF Margin changed N/A year-over-year to 3042.66%; the TTM figure through Jun 2026 stood at 2724.11% (changed N/A YoY), while the FY2025 annual figure was 109.63%, changed N/A from the prior year.
• FCF Margin came in at 3042.66% for Q2 2026 at Seres Therapeutics, up from 4569.83% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 626.21% in Q3 2025 to a low of 19694.19% in Q3 2023.
• Average FCF Margin over 4 years is 5156.83%, with a median of 3823.16% recorded in 2022.
• The largest YoY upside for FCF Margin was 581811 bps in 2023 against a maximum downside of 1792796 bps in 2023.
• Over 4 years, FCF Margin stood at 5779.79% in 2022, then soared by 101 bps to 38.31% in 2023, then slumped by 8883 bps to 3365.07% in 2025, then increased by 10 bps to 3042.66% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 3042.66% in Q2 2026, 4569.83% in Q1 2026, and 3365.07% in Q4 2025.